MIRA PHARMACEUTICALS, INC.

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

0.75 on 9 Oct 2026

0 buys0 sales at will0 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Net income

$10.44M

Free cash flow

$4.66M

Return on equity

-100.5%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
20 Nov 2024	Aminov Erez Chief Executive Officer	Sold on a plan	$56.63K	4.0%
19 Nov 2024	Aminov Erez Chief Executive Officer	Sold on a plan	$77.02K	4.8%
28 Aug 2024	McNulty Brian Patrick 10% owner	Sold at will	$392.00K	7.3%
21 May 2024	Aminov Erez Chief Executive Officer	Bought	$8.18K	2.3%
11 Dec 2023	McNulty Brian Patrick 10% owner	Sold at will	$71.50K	6.5%
8 Dec 2023	McNulty Brian Patrick 10% owner	Sold at will	$30.63K	2.7%

38out of 100

Profitability 0

Financial strength 75

Growth n/a

Insiders 50

Strongest on financial strength (75), weakest on profitability (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$0.00

0 sales

Planned sales

n/a

under a 10b5-1 plan